Manesh Girn, PhD

- Lead corporate strategy and long-term vision for a regenerative neurology biotechnology platform focused on non-hallucinogenic neuroplastogens - Define and lead development strategy translating psychedelic-derived plasticity biology into scalable small-molecule therapeutics - Direct preclinical and translational roadmap, including target selection, pharmacology strategy, and regulatory positioning - Oversee IP strategy and portfolio development - Guide capital strategy, investor relations, and external partnerships - Build and lead a scientific and advisory team spanning medicinal chemistry, in vivo pharmacology, and translational neuroscience - Define corporate narrative and field positioning within regenerative neurology and next-generation CNS therapeutics

- Lead scientific vision and research strategy focused on how psychedelics can be leveraged for creativity and insight in professional and technical contexts - Design and oversee translational research initiatives bridging psychedelics, creativity science, and real-world innovation contexts - Build and steward academic collaborations with leading researchers and institutions - Shape the organization’s long-term scientific roadmap and impact model - Translate emerging findings into strategic initiatives, convenings, and field-building efforts

Advising on study design and scientific strategy related to the brain mechanisms and clinical applications of the psychedelic molecule, 5-MeO-DMT.

Conducting research on the brain and psychological mechanisms underlying the psychedelic experience and psychedelic-assisted psychotherapy, with a primary focus on psilocybin.

- advising on IP strategy - clinical trial protocol development, study design, and their implementation - leading or overseeing the writing of various research documents (e.g., literature reviews, clinical trial protocols, therapy manuals, internal documents, etc.) - investigating and vetting relevant technologies, platforms, and interventions for our clinic - writing blog posts disseminating scientific research related to psychedelics, neuroscience, psychopharmacology, and mental health - leading the development of a novel natural psilocybin formulation

- advising the HHP-Canada Executive Director on building and implementing HHP-Canada’s programming and operating models - informing HHP-Canada’s program design and implementation process by: - Reviewing program plans, objectives, structures, and outcomes - Defining any program data collection protocols and reporting measures - Defining additional appropriate measurement and evaluation criteria for HHP-Canada - Supporting HHP-Canada’s future efforts to improve and scale its programs

- I conducted original neuroimaging (fMRI) research focused on (I) the brain basis of psychedelic drug effects in humans and (II) the relationship between a network of brain regions referred to as the 'default-mode network' and cognition

- Wrote and hosted two series of educational videos on psychedelic science - Hosted a podcast series, interviewing leaders in the field of psychedelic science - Wrote and recorded an "Introduction to Psychedelic Science" audio program

- Co-wrote an Investigator's Brochure (IB) for lysergic acid diethylamide (LSD)

- worked in the Cognitive Neuroscience of Thought Lab, supervised by Dr. Kalina Christoff - worked 2014-2017 as a volunteer research assistant, and 2017-2018 as a full-time paid research assistant and lab coordinator - assisted with and led multiple research projects and research papers, assisted with grant writing, managed lab financial and administrative tasks